Ginkgo Bioworks agreed to acquire Zymergen for $300 million in July 2022, though the company remains publicly traded. After going public in April 2021, the company faced manufacturing difficulties and revealed in August 2021 that its flagship Hyaline product was unsuccessful, causing stock prices to plunge. The company has restructured around three business pillars: Advanced Materials, Drug Discovery, and Automation.
Cyborg Score Rationale
Zymergen faces significant structural challenges including a failed flagship product launch (Hyaline), persistent losses despite $883M in historical funding, and major restructuring. Big banks settled a Zymergen IPO investor suit for $125 million in March 2026, reflecting investor dissatisfaction. The company remains operationally challenged with only 49 employees as of January 2026.
Top Insights
As of January 31, 2026, Zymergen has only 49 employees, reflecting substantial downsizing since its IPO peak
The company has raised a total of $883M across 5 funding rounds, but failed to translate significant capital into sustained revenue
Zymergen has made 3 acquisitions across genomics, life sciences platforms and tools, and infectious diseases sectors, including Lodo Therapeutics, EnEvolv and Radiant Genomics
The company's market capitalization is approximately $253.58M as of February 2026, representing severe shareholder value destruction from its IPO valuation
Named Competitors
Ginkgo Bioworks — Synthetic biology platform for cell engineering
Twist Bioscience — DNA synthesis and gene editing technology
Standard BioTools — Biotech tools and platforms for research
Recent Developments
(March 2026) Big banks settled Zymergen IPO investor securities class action for $125 million
(January 2026) Employee count declined to 49, indicating ongoing restructuring
(May 2021) Acquired Lodo Therapeutics for development of novel therapeutics using AI
Open the full interactive Zymergen Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.